Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.

PharmacoEconomics
Gillian M Keating, Katherine A Lyseng-Williamson

Abstract

Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Well designed clinical trials indicate that varenicline is an effective aid to smoking cessation. During the last 4 weeks of treatment, carbon monoxide-confirmed continuous abstinence rates were generally significantly higher with varenicline than with placebo, bupropion sustained release (SR) or nicotine replacement therapy. Varenicline also reduced cravings, the reinforcing effects of smoking and some withdrawal symptoms. Another well designed trial demonstrated that extending varenicline therapy by an additional 12 weeks helped maintain abstinence in individuals who had quit smoking. Varenicline was generally well tolerated in clinical trials; nausea, the most commonly occurring adverse event, diminished over time. More data are needed regarding the potential for neuropsychiatric events in varenicline recipients. Some of these events may be associated with nicotine withdrawal, rather than varenicline, although neuropsychiatric events have been observed in individuals who continued to smoke whilst receiving varenicline. In modelled cost-effectiveness analyses b...Continue Reading

References

Mar 4, 1999·The New England Journal of Medicine·D E JorenbyT B Baker
Aug 6, 2000·JAMA : the Journal of the American Medical Association·M J ThunS J Henley
Mar 22, 2002·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Elizabeth A KrallRaul I Garcia
Jan 24, 2004·BMJ : British Medical Journal·Richard Edwards
Nov 13, 2004·Preventive Medicine·David W WetterEllen R Gritz
Jul 6, 2006·JAMA : the Journal of the American Medical Association·David GonzalesUNKNOWN Varenicline Phase 3 Study Group
Jul 6, 2006·JAMA : the Journal of the American Medical Association·Douglas E JorenbyUNKNOWN Varenicline Phase 3 Study Group
Jul 6, 2006·JAMA : the Journal of the American Medical Association·Serena TonstadUNKNOWN Varenicline Phase 3 Study Group
Oct 19, 2006·CNS Drugs·Gillian M Keating, M Asif A Siddiqui
Apr 12, 2007·Journal of Occupational and Environmental Medicine·Kenneth C JacksonDiana Brixner
May 15, 2007·Preventive Medicine·N T KjaerK R Olsen
Aug 3, 2007·The American Journal of Psychiatry·Izchak Kohen, Neil Kremen
Aug 3, 2007·The American Journal of Psychiatry·Robert Freedman
Nov 21, 2007·Current Medical Research and Opinion·Martine HoogendoornMaureen P M H Rutten-van Mölken
Mar 26, 2008·The American Journal of Medicine·J Taylor HaysAmit Sood
May 8, 2008·JAMA : the Journal of the American Medical Association·Stacey A KenfieldGraham A Colditz
Jun 4, 2008·The American Journal of Psychiatry·Claudia L Reardon, Robert M Factor
Jun 4, 2008·The American Journal of Psychiatry·Michael K Popkin
Jul 19, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Douglas C A TaylorDavid Thompson
Aug 21, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Pejman PirmoradiSofia S Nadeem
Sep 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·J Taylor Hays
Dec 11, 2008·Vascular Health and Risk Management·Laurence M Galanti
Dec 20, 2008·Lancet·Karen E Lasser, J Wesley Boyd
Feb 5, 2009·Respirology : Official Journal of the Asian Pacific Society of Respirology·Chen WangSimon Davies
Feb 10, 2009·The Journal of Clinical Psychiatry·Lucy I SpirlingGay Sutherland
Feb 25, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Kate CahillTim Lancaster
Apr 10, 2009·PharmacoEconomics·Ataru IgarashiKiichiro Tsutani
Apr 23, 2009·The Annals of Pharmacotherapy·Tara L PurvisRichard H Pham
May 5, 2009·The American Journal of Psychiatry·Pekka LaineSari Lindeman
May 23, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Rachna KasliwalSaad A W Shakir

❮ Previous
Next ❯

Citations

Jul 6, 2010·Cardiovascular Drugs and Therapy·John J McNeilLisa L Ioannides-Demos
May 6, 2011·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Daniel KotzRobert West
Feb 15, 2012·Cognitive and Behavioral Neurology : Official Journal of the Society for Behavioral and Cognitive Neurology·Daniel TranelAntoine Bechara
Oct 1, 2011·BMC Clinical Pharmacology·Lawrence K LeungWalter W Rosser
Mar 10, 2011·BMC Research Notes·Lindsay E LoughThomas G McLeod
Sep 3, 2010·CNS Drugs·Gillian M Keating, Katherine A Lyseng-Williamson
Mar 22, 2014·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Toru KatoKoichi Node
Mar 17, 2012·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Christine E Kistler, Adam O Goldstein
Dec 24, 2015·Talanta·Ramzia I El-BagaryMarwa A El-Wahab Mohamed
Oct 1, 2011·Health Policy·Kristian BolinKoo Wilson
May 18, 2011·Obstetrics and Gynecology Clinics of North America·Shannon M Clark, Ramzy Nakad

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Academic Medicine : Journal of the Association of American Medical Colleges
C CzarneckiJ H Flaherty
© 2021 Meta ULC. All rights reserved